Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study used advanced single-cell RNA and chromatin sequencing to investigate differences in peripheral blood cells between mild and severe alopecia areata patients, uncovering shared transcription factor motifs that may explain disease severity and open avenues for future research on therapeutic targets.

In this study, women with PCOS who took 12 mg of Astaxanthin daily for 8 weeks showed a reduction in certain inflammatory markers and apoptosis-related genes, suggesting potential benefits for managing PCOS, though effects on symptoms like BMI and hirsutism were not significant.

This study presents a new method called scMC that effectively distinguishes biological from technical variation in single-cell genomics datasets, demonstrating its ability to accurately align and detect biological signals across various experiments.

This study developed an animal model that recreates alopecia areata by injecting healthy human skin grafts in immunocompromised mice with peripheral blood mononuclear cells enriched for NKG2D+ and CD56+ cells.

This study suggests that cultured hair follicle dermal sheath cup cells exhibit immune privilege properties, partly through the expression of PD-L1, which impacts co-cultured immune cells' behavior.

This study found that DNA methylation and histone modification status were altered in peripheral blood mononuclear cells of patients with alopecia areata, suggesting these changes may contribute to the disease's pathological immune responses.

This study identified a novel G207E STING mutation associated with severe inflammatory symptoms and suggested that common polymorphisms in TMEM173 and IFIH1 may modify the phenotype in affected individuals.

Alopecia areata patients have more activated T cells in their blood, which may help in developing treatments.

This study found that exosomes from different mesenchymal stem cell sources had distinct effects on immune cell functions and varied microRNA expression profiles compared to their original cells.

This study identified somatostatin as a potential secretory factor contributing to the immune privilege of human hair follicles.

In this study, iNKT10 cells were found to play a significant role in preventing and treating alopecia areata in a humanized mouse model, suggesting these cells could have potential in managing related autoimmune disorders.

In this study, researchers developed a new humanized mouse model for alopecia areata that highlights the role of specific immune cells and may aid in discovering new treatments for the disease.

This study observed that Epigallocatechin-3-gallate (EGCG) can inhibit phosphorylation of STAT1 and reduce a specific subset of immune cells in vitro and ex vivo, suggesting a potential role in maintaining immune privilege in alopecia areata.

This study found that intracellular Toll-like receptors were significantly up-regulated in peripheral blood mononuclear cells of alopecia areata patients, suggesting a potential role in inflammatory signaling and pathogenesis.

In this study, hair follicle-derived mesenchymal stromal cells showed potential for immunomodulation, with equivalent or superior responses compared to those from adipose tissue, suggesting a promising alternative cell source.

This study found that alopecia areata patients who responded poorly to topical immunotherapy had impaired peripheral blood mononuclear cell responses to T-cell stimulants.

This article discusses advancements and methodologies in epitope identification for autoimmune diseases, specifically alopecia areata, but does not report new experimental results.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

This study suggests that allogenic human mesenchymal stem cell treatments have potential therapeutic effects by inducing immune tolerance and anti-inflammatory effects in severe alopecia areata patients.

This study reports that a novel gain-of-function mutation in TMEM173, combined with polymorphisms in TMEM173 and IFIH1, results in a distinct clinical phenotype with features of SAVI, including alopecia and photosensitivity.

Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.

This study found that human hair follicle cells suppress immune activity, with somatostatin playing a significant role, suggesting potential applications for treating inflammatory hair loss conditions.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

This study analyzed blood samples from individuals with alopecia areata and found that NKG2D+ immune cells, particularly memory-like NK cells, may better correlate with disease activity compared to CD8+ cells, though significant variability among individuals complicates these findings.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

This study developed a novel method to analyze the effects of COL7A1 mutations using mRNA from peripheral blood mononuclear cells, aiding genetic diagnosis and potential therapies for dystrophic epidermolysis bullosa.

In this study, PBMCs from women with PCOS showed reduced TNF-α production over time, potentially limiting their antitumor response to breast cancer cell lines compared to healthy controls.

In this study, researchers observed that alopecia areata patients showed higher Th1 and Th2 responses against specific melanogenesis-related protein epitopes, suggesting a role in disease activity and potential targets for diagnostics and therapies.

This study found that SM04755, a novel topical drug, inhibited inflammation, keratinocyte proliferation, and fibrosis in vitro and improved skin health in a mouse model of psoriasis, indicating potential as a topical psoriasis treatment.

In laboratory tests and mouse models, this study found that the novel IPC analog SIG-1451 may offer potent anti-inflammatory effects for treating allergic skin inflammation, potentially outperforming some current therapies in specific inflammatory phases.